Recent advances in the treatment of bacteremia have challenged traditional approaches, particularly regarding the duration of antibiotic therapy and the transition from intravenous to oral regimens. This paper reviews these updates, focusing on evidence-based strategies for managing bacteremia caused by Gram-positive and Gram-negative organisms. Criteria for transitioning to oral therapy, clinical decision-making for uncomplicated cases, and evidence supporting shorter antibiotic courses are discussed. This article is a narrative review of the current literature, integrating clinical guidelines, trial data, and specific considerations for diverse pathogens, ensuring a comprehensive perspective.